ArticleCancer research2019
Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 68 citations in OpenAlex.
- Glioma microenvironment: Cellular crosstalk, immunosuppression, and novel therapeutic perspectives.Chinese medical journal · 2026Review
- From molecular pathogenesis to novel Therapeutic approaches - a review of recent advances in the treatment of peripheral T cell Lymphomas.Biomarker research · 2026Review
- The extracellular matrix in cancer-associated fibrosis: molecular mechanisms and clinical relevance.JCI insight · 2026Review
- Photothermal therapy synergizes with CD47 blockade by inducing calreticulin exposure and remodeling the tumor extracellular matrix in oral squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- The anti-aging Klotho protects glioblastoma macrophages from radiotherapy-induced inflammation and predicts immunotherapy response.International journal of cancer · 2025Article
- Targeting macrophages in cancer immunotherapy: Frontiers and challenges.Journal of advanced research · 2025Review
- Ioning out glioblastoma: ferroptosis mechanisms and therapeutic frontiers.Cell death discovery · 2025Review
- Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis.Cancer metastasis reviews · 2025Review
- The role of tenascin-C in tumor microenvironments and its potential as a therapeutic target.Frontiers in cell and developmental biology · 2025Review
- SPDYC serves as a prognostic biomarker related to lipid metabolism and the immune microenvironment in breast cancer.Immunologic research · 2024Article
- Engineered extracellular vesicles enable high-efficient delivery of intracellular therapeutic proteins.Protein & cell · 2024Article
- Deciphering the role of CD47 in cancer immunotherapy.Journal of advanced research · 2024Review
- Article
- Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond.Current issues in molecular biology · 2024Review
- Angiogenesis related genes based prognostic model of glioma patients developed by multi-omics approach.Discover oncology · 2024Article
- Extracellular Matrix Structure and Interaction with Immune Cells in Adult Astrocytic Tumors.Cellular and molecular neurobiology · 2024Review
- Review
- Key Cell-in-Cell Related Genes are Identified by Bioinformatics and Experiments in Glioblastoma.Cancer management and research · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
Glioblastomas (GBM) are highly infiltrated by myeloid-derived innate immune cells that contribute to the immunosuppressive nature of the brain tumor microenvironment (TME). CD47 has been shown to mediate immune evasion, as the CD47-SIRPα axis prevents phagocytosis of tumor cells by macrophages and other myeloid cells. In this study, we established CD47 homozygous deletion (CD47
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.